Skip to main content

Vireo Growth Inc. Announces First Quarter 2025 Results

– Q1 revenue of $24.5 million increased 1.9% year-over-year, in line with expectations for Vireo’s established markets –

– Merger Transactions expected to begin closing in Q2 and further strengthen profitability profile –

MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

 Summary of Key Financial Metrics      
       
 Three Months Ended 
 US $ in millionsMarch 31, 
  2025  2024  Variance 
        
 GAAP Revenue$24.5  $24.1  1.9% 
 GAAP Gross Profit$12.4  $12.2  1.4% 
 Gross Profit Margin50.6%  50.8%  -20 bps 
 SG&A Expenses$7.5  $7.1  6.0% 
 SG&A Expenses (% of Sales)30.5%  29.3%  120 bps
 
 Operating Income (Loss)$2.0  $4.8  -58.5% 
 Operating Income Margin8.1%  19.8%  -1,170 bps
 
 Adjusted EBITDA$6.6  $6.1  8.5% 
 Adjusted EBITDA Margin26.8%  25.2%  160 bps
 
          

Management Commentary

Chief Executive Officer John Mazarakis commented, “First quarter results were in line with our expectations for Vireo’s established markets. We experienced continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of New York adult use sales from our indoor facility. We remain focused on closing our pending merger transactions, expected to begin during the second quarter.”

Balance Sheet and Liquidity

As of March 31, 2025, total current assets excluding New York assets held for sale were $128.5 million, including cash on hand of $86.3 million. Total current liabilities excluding New York assets held for sale and uncertain tax liabilities were $13.3 million. As of March 31, 2025, the Company had a total of 472,078,412 shares outstanding on the treasury method basis using a share price of $0.45.

Merger Transactions

On March 21, 2025, the Company announced that it filed its Definitive Information Circular with respect to its proposed Merger Transactions. The Circular contains proforma financial information for the combined company as well as 2023 and 2024 audited financial information for each of the various Merger Transaction targets. The Company also announced that it has received requisite shareholder approval in connection with the Merger Transactions after soliciting shareholder approvals via written consent.

The Company has obtained required regulatory approvals for its proposed Utah transactions (“Wholesome Cannabis” and the “Arches” technology platform) and is working toward satisfying all other customary closing conditions of the Merger Transactions, which it expects to meet during the second quarter of 2025.

Conference Call and Webcast Information

Vireo management will host a conference call with research analysts today, May 9, 2025, at 8:30 a.m. ET (7:30 a.m. CT) to discuss its financial results for its first quarter ended March 31, 2025. Interested parties may attend the conference call by dialing 1-888-672-2415 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/968886697.

About Vireo Growth Inc.

Vireo was founded as a pioneer in medical cannabis in 2014 and we are fueled by an entrepreneurial drive that sustains our ongoing commitment to serve and delight our key stakeholders, most notably our customers, our employees, our shareholders, our industry collaborators, and the communities in which we live and operate. We work every day to get better and our team prioritizes 1) empowering and supporting strong local market leaders and 2) strategic, prudent capital and human resource allocation. For more information, please visit www.vireogrowth.com.

Additional Information

Additional information relating to the Company’s first quarter 2025 results will be available on EDGAR and SEDAR later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

Contact Information

Joe Duxbury
Chief Accounting Officer
investor@vireogrowth.com
(612) 314-8995

Forward-Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” “transformation,” and “pending,” variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the Company’s expected performance in 2025; the Company’s pending merger transactions, including the expected timing of the closing of such mergers; future shareholder returns; the Company’s future access to liquidity; future growth opportunities for the Company; . These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the Company’s pending mergers, including satisfaction of closing conditions and regulatory and shareholder approval; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Form 10-K for the year ended December 31, 2024, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

Supplemental Information

The financial information reported in this news release is based on unaudited financial statements for the first quarter ended March 31, 2025, and March 31, 2024. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

          
 VIREO GROWTH INC.         
 CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024        
 (Amounts Expressed in United States Dollars, Unaudited and Condensed)        
   March 31,    December 31,   
   2025 2024  
 Assets       
 Current assets:       
 Cash $86,260,997 $91,604,970  
 Accounts receivable, net of credit losses of $259,011 and $254,961, respectively  3,983,466  4,590,351  
 Income tax receivable  11,367,067  12,027,472  
 Inventory  23,343,300  21,666,364  
 Prepayments and other current assets  1,785,664  1,650,977  
 Warrants held  1,751,906  2,270,964  
 Assets Held for Sale  99,941,960  96,560,052  
 Total current assets  228,434,360  230,371,150  
 Property and equipment, net  32,836,175  32,311,762  
 Operating lease, right-of-use asset  7,660,568  7,859,434  
 Intangible assets, net  7,694,517  7,899,328  
 Deposits  421,244  421,244  
 Total assets $277,046,864 $278,862,918  
 Liabilities        
 Current liabilities        
 Accounts payable and accrued liabilities $12,197,467 $10,456,036  
 Long-Term debt, current portion    900,000  
 Right of use liability  1,148,991  1,400,015  
 Uncertain tax liability  34,959,000  33,324,000  
 Liabilities held for sale  89,351,157  89,387,203  
 Total current liabilities  137,656,614  135,467,254  
 Right-of-use liability  16,437,288  16,494,439  
 Other long-term liabilities  37,278  37,278  
 Convertible debt, net  9,874,521  9,862,378  
 Long-Term debt, net  62,603,583  61,438,046  
 Total liabilities $226,609,284 $223,299,395  
 Stockholders’ deficiency        
 Subordinate Voting Shares ($- par value, unlimited shares authorized; 339,475,288 shares issued and outstanding at March 31, 2025 and 337,512,681 at December 31, 2024)      
 Multiple Voting Shares ($- par value, unlimited shares authorized; 278,170 shares issued and outstanding at March 31, 2025 and 285,371 at December 31, 2024)      
 Additional paid in capital  288,381,930  286,999,084  
 Accumulated deficit  (237,944,351) (231,435,561) 
 Total stockholders' equity (deficiency) $50,437,579 $55,563,523  
 Total liabilities and stockholders' deficiency $277,046,864 $278,862,918  
          


        
VIREO GROWTH INC.        
CONSOLIDATED STATEMENTS OF OPERATIONS    
THREE MONTHS ENDED MARCH 31, 2025 AND 2024    
(Amounts Expressed in United States Dollars, Unaudited and Condensed)    
     Three Months Ended 
  March 31, 
     2025     2024  
Revenue $24,540,641  $24,087,315  
Cost of sales       
Product costs  11,695,329   12,146,888  
Inventory valuation adjustments  433,000   (304,000) 
Gross profit  12,412,312   12,244,427  
Operating expenses:       
Selling, general and administrative expenses  7,473,943   7,051,613  
Transaction related expenses  1,244,696     
Stock-based compensation expenses  1,460,850   179,789  
Depreciation  77,102   73,547  
Amortization  180,032   180,034  
Total operating expenses  10,436,623   7,484,983  
        
Gain (loss) from operations  1,975,689   4,759,444  
        
Other income (expense):       
Interest expenses, net  (7,599,517)  (8,722,637) 
Impairment of long-lived assets       
Gain (loss) on disposal of assets     (120,856) 
Other income (expenses)  790,038   1,317,589  
Other income (expenses), net  (6,809,479)  (7,525,904) 
        
Loss before income taxes  (4,833,790)  (2,766,460) 
        
Current income tax expenses  (1,675,000)  (3,945,000) 
Deferred income tax recoveries       
Net loss and comprehensive loss  (6,508,790)  (6,711,460) 
Net loss per share - basic and diluted $(0.02) $(0.05) 
Weighted average shares used in computation of net loss per share - basic & diluted  366,800,177   143,126,330  
          


        
VIREO GROWTH INC.        
CONSOLIDATED STATEMENTS OF CASH FLOWS       
THREE MONTHS ENDED MARCH 31, 2025 AND 2024       
(Amounts Expressed in United States Dollars, Unaudited and Condensed)       
  MARCH 31, 
     2025     2024  
CASH FLOWS FROM OPERATING ACTIVITIES       
Net loss $(6,508,790) $(6,711,460) 
Adjustments to reconcile net loss to net cash used in operating activities:       
Inventory valuation adjustments  433,000   (304,000) 
Depreciation  77,102   73,547  
Depreciation capitalized into inventory  545,262   560,180  
Non-cash operating lease expense  121,038   103,564  
Amortization of intangible assets  180,032   180,034  
Amortization of intangible assets capitalized into inventory  24,778   24,778  
Stock-based payments  1,321,220   179,789  
Warrants held  519,058   (1,327,879) 
Interest Expense  1,213,681   2,015,889  
Accretion  50,284   52,815  
Loss (gain) on disposal of assets     120,856  
Change in operating assets and liabilities:      
Accounts Receivable  606,886   348,817  
Prepaid expenses  (134,688)  290,106  
Inventory  (2,032,109)  299,252  
Income taxes  660,406   175,203  
Uncertain tax position liabilities  1,635,000   3,760,000  
Accounts payable and accrued liabilities  1,818,743   174,340  
Changes in operating lease liabilities  (358,459)  (168,746) 
Change in assets and liabilities held for sale  (3,495,266)  (1,037,417) 
Net cash provided by (used in) operating activities $(3,322,822) $(1,190,332) 
        
CASH FLOWS FROM INVESTING ACTIVITIES:       
PP&E Additions $(1,146,777) $(899,264) 
Deposits     (150,100) 
Net cash provided by (used in) investing activities $(1,146,777) $(1,049,364) 
        
CASH FLOWS FROM FINANCING ACTIVITIES       
Proceeds from warrant exercises  38,516     
Proceeds from option exercises  23,110     
Debt principal payments  (936,000)  (1,050,000) 
Lease principal payments     (71,066) 
Net cash provided by (used in) financing activities $(874,374) $(1,121,066) 
        
Net change in cash $(5,343,973) $(3,360,762) 
        
Cash, beginning of year $91,604,970  $15,964,665  
        
Cash, end of year $86,260,997  $12,603,903  
        


 
VIREO GROWTH INC.
STATE-BY-STATE REVENUE PERFORMANCE
THREE MONTHS ENDED MARCH 31, 2025 AND 2024
 
  Three Months Ended      
  March 31,      
  2025 2024 $ Change % Change 
Retail:            
MN $11,209,204 $10,977,089 $232,115  2 %
NY  1,205,045  1,821,269  (616,224) (34)%
MD  6,819,392  6,801,082  18,310  0 %
Total Retail $19,233,641 $19,599,440 $(365,799) (2)%
             
Wholesale:            
MD  4,089,238  3,353,661  735,577  22 %
NY  936,351  1,134,214  (197,863) (17)%
MN  281,411    281,411  100 %
Total Wholesale $5,307,000 $4,487,875 $819,125  18 %
             
Total Revenue $24,540,641 $24,087,315 $453,326  2 %
             

Reconciliation of Non-GAAP Financial Measures

Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA. EBITDA and Adjusted EBITDA are a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

        
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA       
(Amounts Expressed in United States Dollars, Unaudited and Condensed)       
  Three Months Ended 
  March 31, 
  2025  2024  
Net income (loss) $(6,508,790) $(6,711,460) 
Interest expense, net  7,599,517   8,722,637  
Income taxes  1,675,000   3,945,000  
Depreciation & Amortization  257,134   253,581  
Depreciation and amortization included in cost of goods sold  570,040   584,958  
EBITDA (non-GAAP) $3,592,901  $6,794,716  
Inventory adjustment $433,000  $304,000  
Grown Rogue termination fee included in cost of goods sold  266,667     
Stock-based compensation  1,460,850   179,789  
Transaction related expenses  1,244,696     
Other income  (790,038)  (1,327,879) 
Severance expense  379,916     
Loss on disposal of assets     120,856  
Adjusted EBITDA (non-GAAP) $6,587,992  $6,071,482  
        

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.